Abstract Search

ea0041ep707 | Growth hormone IGF axis - basic | ECE2016

Robust viral clearance capacity of CTP-modified long-acting growth hormone (MOD-4023) downstream production process

Zakar Miri , Moschcovich Laura , Hershkovitz Oren

Background: OPKO Biologics is a clinical-stage public company developing long-acting therapeutic proteins utilizing CTP technology. The technology involves fusion of the C-terminus peptide of human chorionic gonadotropin (hCG), a highly O-glycosylated peptide, to the target protein. CTP enabled the production of a long-acting human growth hormone (hGH) (MOD-4023) that supports a single-weekly injection in growth hormone-deficient patients. MOD-4023 is manufactured as a non-vis...

0 shares

ePoster

ea0041ep701 | Growth hormone IGF axis - basic | ECE2016

Batch-to-batch consistency of a highly o-glycosylated long-acting human growth hormone (MOD-4023)

Moschcovich Laura , Guy Rachel , Felikman Yana , Zakar Miri , Hershkovitz Oren

Background: OPKO Biologics is a clinical-stage public company developing long-acting therapeutic proteins utilizing CTP technology. The technology involves fusion of the C-terminal peptide of human chorionic gonadotropin (hCG), which is highly O-glycosylated, to the target protein. CTP enabled the production of a long-acting human growth hormone (hGH) (MOD-4023), which supports a single weekly injection in growth hormone-deficient patients. MOD-4023 is manufactured as a non-vi...

0 shares

ePoster

Endocrine Abstracts

Robust viral clearance capacity of CTP-modified long-acting growth hormone (MOD-4023) downstream production process

Batch-to-batch consistency of a highly o-glycosylated long-acting human growth hormone (MOD-4023)

BiosciAbstracts